Seletalisib (UCB-5857) is a potent, ATP-competitive, and selective PI3Kδ inhibitor with IC50 of 12 nM.
Seletalisib (UCB-5857) shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (204-303 fold).
Seletalisib (UCB-5857) blocks AKT phosphorylation following activation of the B-cell receptor in a B-cell line.
Seletalisib (UCB-5857) blocks human T-cell production of several cytokines from activated T-cells, and inhibits B-cell proliferation and cytokine release.
Seletalisib (UCB-5857) dose-dependently inhibits anti-CD3-antibody-induced interleukin 2 release in mice.
